

Effect of bariatric surgery on long-term cardiovascular outcomes

A nation-wide nested cohort study

Osama Moussa* (Specialty Trainee¹) & Maddalena Ardissino* (Academic Foundation Trainee^{2,3}), Tobias Heaton (Medical Student²), Alice Tang (Academic Foundation Trainee²), Omar Khan (Consultant Upper GI Surgeon⁴), Paul Ziprin (Honorary Clinical Senior Lecturer², Consultant General Surgeon¹) Ara Darzi (Paul Hamlyn Chair of Surgery¹); Peter Collins (Professor of Clinical Cardiology², Consultant Cardiologist⁵), Sanjay Purkayastha (Clinical Senior Lecturer², Consultant General Surgeon¹).

*Co-Authors with equal contribution

¹ St Mary's Academic Unit
Imperial College
Praed Street
London, W2 1NY

² Imperial College London
Exhibition Road
London, SW7 2AZ

³ Magill Department of Anaesthesia, Intensive Care and Pain Management
Chelsea and Westminster Hospital
Fulham Road, London, SW10 9NH

⁴ Department of Upper GI and Bariatric Surgery
St George's University of London
London, SW17 0RE

⁵ Royal Brompton Hospital and National Heart and Lung Institute,
Imperial College London
Sydney Street
London, SW3 6NP
Telephone: +44 207 351 8112
E-mail: peter.collins@imperial.ac.uk

ABSTRACT

Aims: This study aims to evaluate the long-term effect of bariatric surgery on cardiovascular outcomes of patients with obesity.

Methods and Results: A nested cohort study was carried out within the Clinical Practice Research Datalink. The study cohort included the 3,701 patients on the database who had undergone bariatric surgery and 3,701 age, gender and BMI matched controls. The primary endpoint was the composite of fatal or non-fatal myocardial infarction; and fatal or non-fatal ischaemic stroke. Secondary endpoints included fatal or non-fatal myocardial infarction alone, fatal or non-fatal ischaemic stroke alone, incident heart failure and mortality.

Findings: The median follow-up achieved was 11.2 years. Patients who had undergone bariatric surgery had significantly lower occurrence of major adverse cardiovascular events (HR 0.410; 95%CI 0.274-0.615, $p<0.001$). This was mainly driven by a reduction in myocardial infarction (HR 0.412; 95% CI 0.280-0.606, $p<0.001$) and not in acute ischaemic stroke (HR 0.536; 95% CI 0.164-1.748, $p=0.301$). A reduction was also observed in new diagnoses of heart failure (HR 0.403; 95% CI 0.181-0.897, $p=0.026$) and mortality (HR 0.254; 95% CI 0.183-0.353; $p<0.001$).

Conclusion: The results of this large, nation-wide cohort study support the long-term effectiveness of bariatric surgery in reducing the risk of major cardiovascular events and incident heart failure in patients with obesity.

Keywords: obesity, bariatric surgery, myocardial infarction, ischaemic stroke.

Take home message: Bariatric surgery reduces the risk of heart attacks.

Introduction

Over the past fifty years, the global burden of obesity has grown exponentially¹. Among the numerous effects of obesity on global health, the growing incidence of cardiovascular disease (CVD) is one of the most hazardous. The independent causal relationship between obesity and cardiovascular disease has been previously well established²⁻⁴. Beyond this direct effect, metabolic changes associated with obesity including hyperlipidaemia, insulin resistance and hypertension, are independent major risk factors contributing to the development of CVD⁴.

Primary and secondary prevention measures for obesity-related disorders gravitate around the central paradigm of weight reduction. This principle also holds true with regard to cardiovascular disease prevention⁵. However, current evidence on the efficacy of medical and dietary approaches to weight reduction on long-term improvement of cardiovascular outcomes remains conflicted. Overall, studies on pharmacological and lifestyle weight loss methods have thus far failed to demonstrate a clear and reliable clinical benefit⁶.

Strong evidence supports the role of bariatric surgery as a more reliable method of weight reduction than either pharmacological or lifestyle measures⁷⁻¹⁰. For this reason, its use has been steadily increasing in recent years¹¹, though the proportion of eligible patients who undergo the procedure is still extremely low. Recently, a growing interest has developed in exploring its effectiveness not only on weight reduction, but also on the reduction or improvement of obesity-related morbidities such as hypertension, diabetes, mortality and cancer rates¹²⁻¹⁵. Considering the known beneficial effects of bariatric surgery on a number of risk factors for cardiovascular disease, including hypertension and diabetes, it is reasonable to hypothesize that bariatric surgery may be an effective means of improving long-term cardiovascular outcomes of patients with obesity.

The aim of this observational, retrospective nested **cohort** study carried out on a prospectively collected national patient database is to evaluate the effect of bariatric surgery on the long-term occurrence of major adverse cardiovascular events in patients with obesity.

Methods

Data for the study was extracted from the Clinical Practice Research Datalink (CPRD) database. The CPRD is a prospective, ongoing UK-based non-profit governmental research service funded by the National Institute for Health Research (NIHR) and the Department of Health (DoH). The CPRD data collection platform involves 674 General Practice surgeries in the United Kingdom, containing anonymised and coded healthcare records of over 11 million consenting patients dating from 1987 to the present. The design, implementation and maintenance of this database have been previously described¹⁶.

Scientific approval for the study was granted by the Regulatory Agency's Independent Scientific Advisory Committee; and ethical approval was granted by the Health Research Authority IRAS. Project ID: 203143. ISAC approval registration number: 16_140R2. Data access for the study was provided by the Big Data & Analytical Unit (BDAU) at the Institute of Global Health Innovation (IGHI) at Imperial College, London.

Role of the funding source

Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC). The funding source had no involvement in the design, collection, analysis or interpretation of data; or in the writing of the report.

Patient population

For the purpose of this study, access was granted to healthcare records pertaining to patients who had a diagnosis of obesity or ≥ 30 kg/m² during follow up. Patients were excluded if they had been lost to follow up within 12 months of index date, other than due to a fatal event. Furthermore, patients were excluded if they were not eligible for bariatric surgery (BMI < 35 kg/m²) or had suffered a major adverse cardiovascular event before index date. Those with missing age, BMI or gender data were also excluded due to inability to match. A nested cohort study design was implemented on the eligible population: the intervention group consisted of the 3,701 eligible patients among these who had undergone bariatric surgery. The controls were 3,701 age, gender and baseline BMI-matched patients who had not undergone the surgery. The patient selection process is outlined in Supplementary Figure 1. Data pertaining to all included patients was extracted from the database; age, gender, BMI, and the

presence of clinical and treatment factors. These included hypertension (HTN), hyperlipidaemia, diabetes mellitus (DM), smoking, alcohol use, cocaine use, exercise, Charlson comorbidity index, and use of medications such as beta blockers (BB), calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs), statins, aspirin and hormone replacement therapy (HRT). Non-diagnostic variables (smoking, alcohol use, exercise, cocaine use) were manually screened and selected by two co-authors; when in disagreement, the decision was settled by evaluation of a third author. Patients were considered smokers if they had indication of past or present smoking habit, including a direct quantification or referral or advice for smoking cessation. Alcohol use was considered in all patients who had indication of moderate or high alcohol intake, referral or advice for alcohol use cessation, and the diagnosis of any alcohol-related morbidity (i.e. alcoholic hepatitis). Patients were considered to exercise if they had **coded clinical information specifying** mild, moderate or intense regular exercise. Medication use was defined as medication use at any time and for any length during follow up.

Endpoint definition

The primary endpoint was the composite of fatal or non-fatal myocardial infarction; and fatal or non-fatal acute ischaemic stroke. Only ischaemic strokes were considered; intra-cerebral bleeds, traumatic bleeds or sub-arachnoid hemorrhage were **not considered as primary endpoints**. The secondary endpoints considered were new occurrence of heart failure, and we also analysed the primary endpoint components individually: fatal or non-fatal myocardial infarction, and fatal or non-fatal acute ischaemic stroke. All-cause mortality was also considered, as a safety outcome.

Further information regarding the CPRD-specific clinical codes used for endpoint definition in the study is provided in Supplementary Table 1, Supplementary Table 2 and Supplementary Table 3 respectively for stroke, myocardial infarction and heart failure.

Weight change and risk factor modification

The median weight for the two cohorts across follow up time was compared by extracting the index date, and following this the individual weight of each patient per year of follow up; starting from the index date. When a patient had more than one weight reading during the year, the median value among these multiple readings was extracted. **The closest weight to the index date, represented as weight at**

“Time 0”, was also recorded across both groups. Using these readings, the ‘zero’ weight as well as the median weight of the bariatric and control cohorts for each year of follow up was then calculated for each year and graphically represented.

The rates of resolution of Type 2 Diabetes during follow up were assessed. This was defined as either a direct clinical code indicating diabetes resolution, and in patients whose last prescription for any hypoglycaemic or antidiabetic medication occurred more than 6 months before the end of follow-up. The time of diabetes resolution considered for statistical analysis was defined as either the time of entry of a clinical coded diagnosis or the time of last medication prescription; plus six months.

Statistical analysis

The data for the study were extracted, prepared and analysed using the Statistical Package for Social Sciences, version 25 (SPSS Inc., New York, NY, USA)⁹.

Baseline demographic, clinical and treatment factors were compared across cohorts using Pearson’s chi-squared test for categorical variables and Mann-Whitney U test for continuous data. Weight and BMI change across follow-up time, and rates of resolution of diabetes, were also compared across cohorts. This was done respectively using Wilcoxon Rank-sum test and chi-squared test. The Mann-Whitney U was chosen as the data was not normally distributed on Kolmogrov-Smirnov test.

Cox proportional hazards model was used to analyse time to event data adjusting for multiple covariates for both primary, secondary endpoints. Factors adjusted for in the Cox proportional hazards model include hypertension (HTN), hyperlipidaemia, diabetes mellitus (DM), smoking, alcohol use, cocaine use, exercise, and use of medications such as beta blockers (BB), calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs), statins, aspirin, and hormone replacement therapy (HRT). The interaction of gender, diabetes, and BMI category with bariatric surgery on the primary endpoint was tested using Cox proportional hazards model with interaction terms.

The interaction effects of predefined variables were tested using a Cox proportional hazards model with interaction terms. The cumulative event rates by bariatric surgery type were also assessed by means of a Kaplan Meier analysis, and the relative rates across groups compared using a log-rank function.

The number of interventions needed to prevent a single cardiovascular event over 11·2 years (and therefore the number needed to treat [NNT]) was calculated as the reciprocal of the absolute risk reduction between the surgery and control cohorts. All p values reported are 2-sided; statistical significance was considered when $P < 0\cdot05$.

Results

Baseline characteristics

A total of 7,402 patients were included in the analysis; of which 3,701 had undergone bariatric surgery and 3,701 had not. The average length of follow-up was 140.7 months (SD=79.9 months), equating to 86,603 person-years. The median age was 36.00 years across both cohorts; and the median BMI was 40.3 kg/m² in the bariatric surgery group, and 40.5 kg/m² in the group who had not undergone bariatric surgery.

The baseline clinical and treatment characteristics of patients subdivided by cohort are described in Table 1. Overall, risk factors for cardiovascular disease were more prevalent among patients in the bariatric surgery group at baseline. These include hypertension (p=0.014) and use of hormone replacement therapy (p=0.007). On the other hand, cocaine (p=0.012) and beta-blocker use (p=0.037) were less frequent in the bariatric surgery cohort. Charlson comorbidity index was similar across the two cohorts (p=0.071), though a non-significant trend towards higher baseline morbidity in the bariatric surgery cohort was observed.

Primary endpoint

During follow-up, the primary endpoint of fatal or non-fatal myocardial infarction or ischaemic stroke occurred in 130 patients; 37 events occurred in patients that had undergone bariatric surgery, while 93 occurred in patients who had not (HR 0.410; 95%CI 0.274-0.615, p<0.001, NNT=62). The results of the analysis are outlined in Table 2; and depicted in Figure 1. Twelve patients experienced more than one event: 3 in the bariatric surgery group, and 9 in the control group.

Myocardial infarction occurred less frequently in the bariatric surgery cohort (36 vs 93; HR 0.412; 95% CI 0.280-0.606, p<0.001, NNT=64). Ischaemic stroke rates not significantly different across cohorts (13 vs 4; HR 0.536; 95% CI 0.164-1.748, p=0.301), as displayed in Supplementary Figure 2 and 3.

Sixty-eight patients received a new diagnosis of heart failure during follow up; of whom 22 belonged to the bariatric surgery group, and 46 to the control group (HR 0.403; 95% CI 0.181-0.897, p=0.026, NNT=153), as displayed in Table 2 and Figure 2A. All-cause mortality was lower in the bariatric

surgery cohort (45 vs 182 HR 0.254; 95% CI 0.183-0.353; $p < 0.001$, NNT=27), as displayed on Table 2 and Figure 2B.

Secondary analysis

Patients in the bariatric surgery cohort experienced significantly more weight loss during follow up compared to patients in the control group [Median -4.22kg (-19.3-8.0) vs. +6.00kg (-2.9-16.7); Z -25.15; $p < 0.001$]. The median weight of patients across follow up time are depicted in Figure 4. Among those with type 2 diabetes at baseline, in the bariatric surgery cohort had significantly higher rates of resolution (371 vs. 107; HR 3.97; 95%CI 3.20-4.93; $p < 0.001$).

The number and proportion of all patients who underwent different bariatric surgery types, and primary endpoint rates by surgery type are displayed in Supplementary Table 4. The type of bariatric surgery was found not to significantly impact primary endpoint rates (logrank $p = 0.994$).

Interaction analysis

A total of 1,803 patients in the study had diabetes; of these, 881 belonged to the control group and 922 to the bariatric surgery group. Diabetes did not significantly interact with bariatric surgery in the determination of primary endpoint (p for interaction = 0.529). Patients with diabetes who underwent bariatric surgery displayed an association with lower heart failure rates (HR 0.278; 95%CI 0.120-0.642, $p = 0.003$) whereas those with no diabetes did not (HR 0.780; 95%CI 0.362-1.681; $p = 0.527$). Though a trend was observed for this interaction, it did not fulfill statistical significance (p for interaction = 0.077).

Females made up a total of 79.8% of both the bariatric surgery cohort and the control cohort. Gender did not significantly interact with bariatric surgery for the primary endpoint (p for interaction=0.148), and for heart failure (p for interaction = 0.622). Patients were equally split between bariatric surgery patients and control due to baseline matching. BMI category was found to not interact significantly for primary events (p for interaction $p = 0.682$) and for occurrence of incident heart failure (p for interaction = 0.263).

The results of the interaction analysis are displayed in Figure 3 and Table 3.

Discussion

In this nation-wide nested cohort study, bariatric surgery was associated with significantly lower incidence of major adverse cardiovascular events - defined as fatal and non-fatal myocardial infarction and stroke - and also lower rates of incident heart failure and mortality in a cohort of patients with obesity. These results were observed in spite of the presence of a greater number of classical risk factors typically used for the short-term risk prediction of cardiovascular events in the bariatric surgery group at baseline.

Acute cardiovascular events are one of the largest and most hazardous consequences of obesity. Despite the well-recognised causal relationship between obesity and cardiovascular disease⁴, studies assessing the effect of lifestyle and medical weight reduction interventions have thus far yielded extremely conflicting results.

On the other hand, a small but growing pool of evidence assessing the impact of weight loss surgery on cardiovascular outcomes has begun to yield encouraging results. Randomised evidence supports the beneficial effect of bariatric surgery on a number of cardiovascular risk factors, including diabetes, hypertension and hyperlipidaemia¹⁷⁻¹⁹. However, no prospective randomised evidence is available to quantify the effect of bariatric surgery on long-term cardiovascular events so far. Nevertheless, a protective effect of weight loss surgery has been described in observational studies^{13,20-23}, including in specific populations such as those with type 2 diabetes²⁴⁻²⁶, and better outcomes after myocardial infarction²⁷, and in the CPRD cohort Douglas et al¹⁹; demonstrated higher weight loss alongside reductions in a number of obesity related risk factors in bariatric surgery patients. To date, the Swedish Obese Study (SOS) remains the most comprehensive ongoing investigation. The results of our study, on a larger population of 7,402 patients with no age restriction and a follow up time of up to 38 years (average 11.2 years); are in line with findings of the SOS²⁸.

In this study, the lower cardiovascular event rate observed in the bariatric surgery cohort occurred alongside a higher rates of resolution of type 2 diabetes and a greater degree of weight loss. Bariatric surgery patients tended towards greater weight at index time, though the variation was large; and lost significantly more weight during the study period and were thus lighter at the end of follow-up. This implies that the protective effect observed may be mediated by a substantial modification in cardiovascular risk factors. The protective effect indeed displayed a late and widening diversion of

event curves that became most evident approximately 8 years after the surgery. This pattern of event curve diversion is analogous to that observed across other risk-factor modifying strategies, such as lipid-lowering therapies, which would be consistent with the known benefit of bariatric surgery on metabolic risk factor control.

Though this is one of the largest cohort studies on bariatric surgery patients thus far, there were unfortunately still not enough patients and event numbers to directly explore whether diabetes resolution may have mediated the reduction in cardiovascular events observed in the bariatric surgery cohort through a specific interaction analysis. We did, however, find some evidence of potential interaction between diabetes and incident heart failure. This certainly calls for further investigation, especially in light of the higher rates of diabetes resolution in the bariatric surgery cohort compared to the controls.

The CPRD is an extremely rich database that has previously been shown to accurately represent the UK population in terms of age, sex and ethnicity; the findings of this study are therefore generalisable to the population of the United Kingdom and most western countries of similar demographic profile. However, a limitation of the database lies in its potential for significant diagnostic variability. Misdiagnoses, erroneous entries and variations in terminology may all impact the reliability of the data and may exert a non-negligible impact. Despite this, attempts to validate the diagnoses with linked secondary care records have thus far been successful²⁹; though none have targeted the accuracy and completeness of major cardiovascular event records thus far. Furthermore, the lack of access to laboratory data prevented the ability to follow-up changes in inflammatory markers, glucose control and lipid levels after bariatric surgery, and to cross-validate and enhance diagnoses (i.e. hyperlipidaemia) with corresponding laboratory data. The lack of access to causes of mortality is also an important limitation that prevents us from being able to assess specific cardiovascular mortality in the cohort.

Finally, of paramount importance is the potential limitation arising from unmeasured factors. This is a global limitation of the retrospective nature of the study. Despite post-hoc adjustment for covariates, a number of factors that are impossible to quantify from retrospective data (i.e. motivation levels, health seeking behaviors, healthcare engagement) that are likely more prevalent among the bariatric surgery cohort, both as a selection bias and as a consequence of more intensive follow up and screening

engagement for the surgery, may have conceivably impacted the long-term outcomes, and have thus augmented the strength of the association shown in this study. Ideally, the findings of this study should thus be confirmed by a prospective randomised study.

In conclusion, the present study provides evidence of a potential protective effect of bariatric surgery on the long-term risk of acute cardiovascular events and incident heart failure in a large, nation-wide comprehensive cohort of patients followed up for a median time of 11.2 years. With a number needed to treat of 62 to prevent one cardiovascular event over only 11.2 years, the potential overall lifetime benefit that this study implies is large. Considering that currently less than 1% of eligible patients undergo bariatric surgery³⁰, and considering the wealth of emerging evidence on its far-reaching benefits that range from mental health to cancer and cardiovascular risk, it is time to investigate, consider and amend the barriers creating this treatment gap in order to provide the best standard of care and optimize long-term outcomes of patients with obesity.

Acknowledgements

Data access was provided by the Big Data & Analytical Unit (BDAU) at the Institute of Global Health Innovation (IGHI), Imperial College London.

Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC).

Conflict of interest: none declared.

References

1. WHO. WHO | Obesity and overweight. *World Heal Organ Media Cent Fact Sheet No 311*. 2011:1-2.
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. *Circulation*. 1983;67(5):968-977.
3. Mayor S. Obesity in middle age is an independent risk factor for cardiovascular disease. *BMJ*. 2006;332(7533):71.2.
4. Yusuf PS, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet*. 2004;364(9438):937-952.
5. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano A, Cooney MT, Corra U, Cosyns B, Deanon C, Graham I, Hall MS, Hobbs FDR, Locher ML, Lolligen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter D, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2016;37(29):2315-2381.
6. Diabetes Prevention Program Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009 Dec 19;374(9707):2054.
7. IBM. IBM SPSS Statistics Software for Windows, Version 25. IBM.
8. Gloy VL, Briel M, Bhatt DL, SR Kashyap, PR Schauer, G Mingrone, HC Bucher, AJ Nordmann. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2013;347(oct22 1):f5934-f5934.
9. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis *JAMA*. 2004;292:1724-1737.
10. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study

- Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med.* 2004;351(26):2683-2693.
11. Booth HP, Khan O, Fildes A, Prevost AT, Reddy M, Charlton J, Gulliford MC; King's Bariatric Surgery Study Group. Changing Epidemiology of Bariatric Surgery in the UK: Cohort Study Using Primary Care Electronic Health Records. *Obes Surg.* 2016.
 12. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-Term Mortality after Gastric Bypass Surgery. *N Engl J Med.* 2007.
 13. Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA - J Am Med Assoc.* 2014.
 14. Mistry P, Currie V, Super P, le Roux CW, Tahrani AA, Singhal R. Changes in glycaemic control, blood pressure and lipids 5 years following laparoscopic adjustable gastric banding combined with medical care in patients with type 2 diabetes: a longitudinal analysis. *Clin Obes.* 2018.
 15. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol.* 2015. doi:10.1093/ije/dyv098
 16. IBM. IBM SPSS Statistics Software for Windows, Version 25. IBM. doi:10.1016/j.jchf.2014.02.009
 17. Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, Livingston EH, Olsen MK. Bariatric surgery and long-term durability of weight loss. *JAMA Surg.* 2016. doi:10.1001/jamasurg.2016.2317
 18. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 Year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet.* 2015.
 19. Douglas IJ, Bhaskaran K, Batterham RL, Smeeth L. Bariatric Surgery in the United Kingdom:

- A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care. *PLoS Med.* 2015;12(12):1-18.
20. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lönroth H, Narbro K, Näslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. *JAMA - J Am Med Assoc.* 2012.
 21. Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ, O'Brien R, Bogart A, Theis MK, Anau J, Schroeder EB, Sidney S. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. *JAMA.* 2018;320(15):1570.
 22. Michaels AD, Mehaffey JH, Hawkins RB, Kern JA, Schirmer BD, Hallowell PT. Bariatric surgery reduces long-term rates of cardiac events and need for coronary revascularization: a propensity-matched analysis. *Surg Endosc.* 2019.
 23. Batsis JA, Romero-Corral A, Collazo-Clavell ML, Sarr MG, Somers VK, Brekke L, Lopez-Jimenez F. Effect of weight loss on predicted cardiovascular risk: Change in cardiac risk after bariatric surgery. *Obesity.* 2007. doi:10.1038/oby.2007.589
 24. Aleassa E, Hassan M, Hayes K, A. Brethauer S, R. Schauer P, Aminian A. Effect of revisional bariatric surgery on type 2 diabetes mellitus. *Surg Endosc.* 2019;33.
 25. Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR, Kattan MW, Nissen SE. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. 2019;44195:1-12.
 26. Eliasson B, Liakopoulos V, Franzén S, Näslund I, Svensson AM, Ottosson J, Gudbjörnsdottir S. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: A nationwide, matched, observational cohort study. *Lancet Diabetes Endocrinol.* 2015.
 27. Aminian A, Aleassa EM, Bhatt DL, Tu C, Khorgami Z, Schauer PR, Brethauer SA, Daigle CR. Bariatric surgery is associated with a lower rate of death after myocardial infarction and stroke: A nationwide study. *Diabetes, Obes Metab.* 2019.
 28. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K. Surgical obesity treatment and the risk of heart failure. *Eur Heart J.* 2019.

29. Margulis A V., Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. *Epidemiology*. 2018.
30. Funk LM, Jolles S, Fischer LE, Voils CI. Patient and referring practitioner characteristics associated with the likelihood of undergoing bariatric surgery a systematic review. *JAMA Surg*.

Figures




Figure 1 – Cumulative incidence of adjusted primary endpoints (fatal or non-fatal myocardial infarction and fatal or non-fatal ischaemic stroke).




Figure 2 – Cumulative incidence of secondary endpoints: 2a. incident heart failure; 2b. all cause mortality.




Figure 3 – Interaction analysis for age, baseline BMI and type 2 diabetes: Cox proportional hazards model with interaction effects.




Figure 4 – Median weight change by cohort during follow up (Median, IQR).

Supplementary Material

Supplementary Figure 1 – Patient selection flowchart

Supplementary Figure 2 - Adjusted primary endpoint component rates: myocardial infarction.

Supplementary Figure 3 - Adjusted primary endpoint component rates: ischaemic stroke.

Supplementary Table 1 – Clinical diagnosis codes used for ischaemic stroke endpoint definition

Supplementary Table 2 – Clinical diagnosis codes used for myocardial infarction endpoint definition

Supplementary Table 3 – Clinical diagnosis codes used for heart failure endpoint definition

Supplementary Table 4 – Primary endpoint rates by bariatric surgery type